Hyderabad-based HRV Pharma has acquired the German wholesaler Phatebo GmbH to enter the European clinical trial supply market. The move marks a shift from active ingredients to finished medicines as the company reportedly prepares for a 2027 IPO.
Hyderabad-based HRV Pharma has finalized a definitive agreement to acquire 100% of the equity in Germany-based Phatebo GmbH from its parent, ZeroStack Corp. This acquisition provides the Indian pharmaceutical firm with a strategic foothold in the European clinical trial supply market, marking a significant step in its international growth strategy.
Phatebo, which is based in Hilzingen, specializes in the supply chain logistics for investigational, comparator, and ancillary medicines. The firm recorded approximately ₹350 crore in revenue during 2025. For HRV Pharma, this deal offers more than just revenue; it provides a ready-made regulatory gateway. By utilizing Phatebo’s German pharmaceutical wholesale authorization, HRV Pharma can bypass some of the hurdles usually faced when entering the highly regulated European market from scratch.
This acquisition represents a key change in HRV Pharma’s business strategy. The company has traditionally focused on the production of active pharmaceutical ingredients (APIs). By integrating Phatebo, HRV Pharma is pivoting into the higher-value finished formulations segment. This allows the company to move closer to the end-user in the pharmaceutical supply chain and diversify its revenue sources.
Because HRV Pharma is currently a private entity, its shares are not traded on the National Stock Exchange (NSE) or the Bombay Stock Exchange (BSE). However, industry reports suggest that the company is preparing for an initial public offering (IPO) in the first half of 2027. Investors and sector watchers may view this expansion as an attempt to strengthen the company’s portfolio and revenue visibility ahead of its potential public debut.
While the expansion offers growth potential, it also brings specific business risks. Expanding into the European market involves strict adherence to European Good Distribution Practice (GDP) standards. Successfully integrating a foreign subsidiary requires robust operational oversight to maintain these quality systems. Furthermore, the pharmaceutical industry continues to face pressures from geopolitical instability, potential changes in international trade tariffs, and logistics disruptions. The company’s ability to navigate these cross-border regulatory and supply chain challenges will be critical to sustaining the profitability of the new European venture.
The next important monitorable for those tracking the company will be its progress in integrating Phatebo’s operations into its existing business model, alongside any further updates regarding its planned 2027 IPO timeline.